Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Study limitation reported by the research below: “Specific JAK inhibitor agents (e.g., tofacitinib, baricitinib, upadacitinib) and IL-6Ri agents (e.g., tocilizumab, sarilumab) are not broken out individually in the abstract — class-level findings may mask drug-specific differences.”